Key facts
- OaCP’s last known valuation is $7.7M.
- It has raised $700K.
- Notable investors include SOSV, Almacube, Bio4Dreams, EIT Health, Interreg North-West Europe — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for OaCP
- ·The full record, as it builds
Funding rounds
No funding rounds for OaCP are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OaCP
Developer of molecular diagnostic reagents designed to accelerate genetic testing workflows and improve oncology patient outcomes. The company offers patent-protected chemical catalysts compatible with existing laboratory processes and approved under in vitro diagnostic regulations, enabling clinical laboratories and diagnostic providers to shorten DNA hybridisation time, reduce testing costs, and maintain high levels of diagnostic accuracy.
- Sector
- Healthcare
- HQ
- Clonakilty, Ireland
- Founded
- 2017
- Employees
- 6
- Ownership
- Privately Held (backing)
OaCP doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OaCP shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OaCP in its N-PORT filings yet. We sweep new filings monthly.